United States · FDA National Drug Code directory
FLUBLOK TRIVALENT NORTHERN HEMISPHERE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 49281-726_92606719-3e37-477b-baf9-453cb34f3f50
- Product NDC
- 49281-726
- Form
- INJECTION
- Composition / generic term
- INFLUENZA A VIRUS A/Missouri/11/2025 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN, INFLUENZA A VIRUS A/Darwin/1415/2025 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN, and INFLUENZA B VIRUS B/Pennsylvania/14/2025 RECOMBINANT HEMAGGLUTININ ANTIGEN
- Labeler
- Sanofi Vaccines US Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20260702 / 20270630
Source-listed ingredients
- INFLUENZA A VIRUS A/MISSOURI/11/2025 (H1N1) RECOMBINANT HEMAGGLUTININ ANTIGEN — 45 ug/.5mL
- INFLUENZA A VIRUS A/DARWIN/1415/2025 (H3N2) RECOMBINANT HEMAGGLUTININ ANTIGEN — 45 ug/.5mL
- INFLUENZA B VIRUS B/PENNSYLVANIA/14/2025 RECOMBINANT HEMAGGLUTININ ANTIGEN — 45 ug/.5mL
These values do not establish equivalence or a dose recommendation.
Packages
- 10 SYRINGE in 1 CARTON (49281-726-10) / .5 mL in 1 SYRINGE (49281-726-88) · 49281-726-10
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →